Financial Performance - The company's operating revenue for 2019 was CNY 1,927,593,214, representing a 4.03% increase compared to CNY 1,852,905,951 in 2018[19]. - The net profit attributable to shareholders decreased by 20.85% to CNY 83,974,764 in 2019 from CNY 106,091,390 in 2018[19]. - The net profit after deducting non-recurring gains and losses was CNY 82,210,889, down 14.95% from CNY 96,664,626 in the previous year[19]. - The cash flow from operating activities net amount was CNY 128,279,888, a decrease of 13.63% compared to CNY 148,525,997 in 2018[19]. - The total assets at the end of 2019 were CNY 3,556,129,011.94, reflecting a 13.74% increase from CNY 3,126,491,309.12 at the end of 2018[19]. - The net assets attributable to shareholders increased by 3.03% to CNY 2,616,935,698.11 at the end of 2019 from CNY 2,539,856,196.66 at the end of 2018[19]. - The company's basic and diluted earnings per share decreased by 20% to CNY 0.16 compared to the previous year[20]. - The total profit for 2019 was 108.26 million yuan, a decrease of 13.37% compared to the previous year[53]. - The net profit attributable to shareholders was 83.97 million yuan, down 20.85% year-on-year, with a diluted earnings per share of 0.16 yuan, a decrease of 20%[53]. - By the end of 2019, total assets reached 3,556.13 million yuan, an increase of 13.74% year-on-year, while net assets attributable to shareholders rose by 3.03% to 2,616.94 million yuan[53]. Revenue Segmentation - The revenue from the pharmaceutical manufacturing segment accounted for 75.05% of total revenue, reflecting the company's strong market position[28]. - The pharmaceutical commercial segment contributed 24.95% to total revenue, indicating a diversified revenue stream[28]. - The company reported a total revenue increase of 4.03% year-on-year, driven by higher sales in pharmaceutical manufacturing[20]. - The pharmaceutical manufacturing industry achieved a main business revenue of CNY 23,908.6 billion in 2019, growing by 7.4% year-on-year, which is 3.6 percentage points higher than the overall level of large-scale industrial enterprises in the same period[33]. - The total profit of the pharmaceutical manufacturing industry reached CNY 3,119.5 billion in 2019, an increase of 5.9% year-on-year, exceeding the overall profit growth of large-scale industrial enterprises by 9.2 percentage points[33]. - The pharmaceutical manufacturing industry's main business profit margin was 13.05%, which is 7.19 percentage points higher than the overall level of large-scale industrial enterprises[33]. Research and Development - The company has established a comprehensive R&D system focusing on eight major therapeutic areas, enhancing its competitive edge in the industry[29]. - The company has been actively involved in patent development, applying for 10 patents in 2019, including 6 invention patents and 3 utility model patents[50]. - The total R&D expenditure amounted to ¥19,959,124.19, representing 1.04% of total revenue[83]. - The R&D investment for the sodium cantharidate series products was CNY 9,386,850.79, accounting for 0.49% of operating revenue, which represents a decrease of 49.46% compared to the previous year[102]. - The company is focusing on the efficacy comparison studies of sodium cantharidate against other mainstream anti-tumor drugs in the market[98]. - The company is conducting industrialization research on the production process of the unique compound amino acid (8) vitamin (11) capsules, which is crucial for ensuring product stability[98]. - The company has initiated quality standard enhancement research for nine types of traditional Chinese medicinal materials, which will improve the quality standards of related products[99]. Market Strategy and Operations - The company has established a professional sales team and a marketing management model, covering most provinces in China, with a focus on both OTC and prescription drug sales[31]. - The company emphasizes a procurement strategy for key raw materials and packaging materials through bidding to ensure compliance and efficiency[30]. - The company adheres to a production model based on "sales-driven production," ensuring effective coordination among procurement, manufacturing, logistics, and sales[30]. - The company actively participates in bidding for grassroots medical institutions and expands its market presence in mature regions[31]. - The company is focusing on expanding its market presence and product lines, particularly in the fields of oncology and cardiovascular treatments[49]. - The company plans to continue expanding its product lines and enhance its market presence in the pharmaceutical sector[72]. Compliance and Risk Management - The company has disclosed potential risks in its annual report, particularly regarding future development strategies[7]. - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors[6]. - The company is exposed to risks from stricter environmental regulations, which may increase costs related to pollution control and impact profitability[143]. - The company is adjusting its product protection strategies and enhancing dynamic management capabilities in response to regulatory changes[141]. - The company is at risk of not winning bids in medical insurance tenders, which could adversely affect its operating performance[144]. - The company has established a dynamic monitoring mechanism for industry policy changes to adapt to regulatory shifts and maintain profitability[139]. Corporate Governance - The company has established a governance structure that complies with the Company Law and Securities Law, ensuring effective operation of the corporate governance system[199]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of one-third independence[200]. - The supervisory board conducts regular meetings to oversee the legality and compliance of the company's financial practices and management responsibilities[200]. - The company respects the legitimate rights of stakeholders, including banks, creditors, employees, suppliers, and sales merchants, promoting sustainable development[200]. Social Responsibility - The company donated medicines valued at approximately RMB 5.4 million to support pandemic prevention efforts during the COVID-19 outbreak[167]. - The company has continued to invest in environmental protection, ensuring compliance with environmental standards and increasing investment in pollution control measures[166]. Employee Management - The company employed a total of 1,475 staff, with 1,466 in major subsidiaries and 9 in the parent company[194]. - The professional composition of employees includes 698 production personnel, 152 sales personnel, 217 technical personnel, 44 financial personnel, and 364 administrative personnel[194]. - The company has implemented a salary system where senior management is on an annual salary basis, while middle and lower-level staff are on a performance-based salary system[195]. - The company plans to conduct various training programs, including legal, ethical, and professional skills training, to enhance employee capabilities[196].

2019 年 10 月 1 / 30 2019 年第三季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2019 年第三季度报告 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 30 2019 年第三季度报告 | （税后） | | | | --- | --- | --- | | 所得税影响额 | -137,478.68 | -307,174.56 | ...

Financial Performance - The company's operating revenue for the first half of 2019 was ¥911,009,600.51, representing a year-on-year increase of 6.30% compared to ¥857,022,515.73 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥57,149,229.91, a decrease of 2.43% from ¥58,570,939.08 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥56,235,803.84, which is an increase of 15.75% from ¥48,585,691.08 in the same period last year[21]. - The net cash flow from operating activities was ¥67,183,416.47, down 31.18% from ¥97,621,314.18 in the previous year[21]. - The total assets at the end of the reporting period were ¥3,432,042,593.35, an increase of 9.77% from ¥3,126,491,309.12 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased to ¥2,596,433,219.94, a rise of 2.23% from ¥2,539,856,196.66 at the end of the previous year[21]. - The basic earnings per share remained at ¥0.11, unchanged from the previous year[22]. - The weighted average return on net assets decreased by 0.12 percentage points to 2.23% compared to the previous year[22]. Revenue Segmentation - The increase in operating revenue was attributed to a rise in pharmaceutical manufacturing sales by ¥45,595,100, an increase of 8.07%[21]. - The pharmaceutical commerce segment also saw an increase of ¥839,200, representing a growth of 2.87%[21]. - The pharmaceutical manufacturing segment accounted for 67.03% of total revenue during the reporting period[28]. - The pharmaceutical commercial segment accounted for 32.97% of total revenue during the reporting period[28]. Cash Flow and Assets - As of the end of the reporting period, cash and cash equivalents increased by 75.02% to CNY 360,220,096.71, representing 10.49% of total assets[46]. - Accounts receivable decreased by 44.26% to CNY 100,416,203.88, accounting for 2.93% of total assets[46]. - Prepayments increased by 70.61% to CNY 166,596,849.01, making up 4.85% of total assets[46]. - Other receivables rose by 67.11% to CNY 328,416,414.95, which is 9.57% of total assets[46]. - Short-term borrowings amounted to CNY 101,080,000.00, indicating a significant increase[47]. - Tax payable decreased by 68.18% to CNY 15,264,789.57, representing 0.44% of total liabilities[47]. Subsidiary Performance - Revenue from the subsidiary Jinqiao Pharmaceutical was CNY 323.99 million, with a net profit of CNY 14.21 million[51]. - Revenue from the subsidiary Magic Pharmaceutical was CNY 152.41 million, with a net profit of CNY 3.28 million[52]. - Revenue from the subsidiary Baiqiang Pharmaceutical was CNY 394.22 million, with a net profit of CNY 43.47 million[52]. Risks and Challenges - The company faces significant policy risks due to increasing regulatory scrutiny in the pharmaceutical industry, which may lead to a decline in overall drug prices and impact future development[53]. - The company is investing heavily in drug research and development, but faces risks related to regulatory approval processes and potential delays in drug registration[54]. - Rising raw material costs due to supply constraints and regulatory pressures may impact the company's profitability, necessitating improved procurement strategies[63]. Corporate Governance and Compliance - The company has not experienced any major product quality issues but acknowledges the potential risks associated with quality control in the pharmaceutical sector[60]. - The company has committed to maintaining the independence of its actual controller and related parties in business operations[69]. - The company has no major litigation or arbitration matters during the reporting period[72]. - The actual controller and major shareholders maintained a good integrity record without any administrative or criminal penalties related to the securities market during the reporting period[73]. Investment and Development - The company is actively developing the efficacy of the sodium cantharidate series products to solidify its leading position in the anti-tumor field[40]. - The company is advancing the construction of its Sha Wen production and R&D base to upgrade its industrial foundation and promote sustainable development[41]. - The company plans to expand its market presence and invest in new product development to drive future growth[143]. - The company is focusing on strategic mergers and acquisitions to enhance its competitive position in the market[143]. Financial Reporting and Accounting - The company’s financial statements comply with the enterprise accounting standards, reflecting its financial status and operational results accurately[158]. - The company’s consolidated financial statements include all subsidiaries under its control, ensuring a comprehensive view of its financial performance[165]. - The company recognizes investment income from the difference between the consideration received from disposals and the fair value of remaining equity investments[167].

Financial Performance - Operating income rose by 23.52% to CNY 426,384,693.33 year-on-year[6] - Net profit attributable to shareholders decreased by 21.34% to CNY 23,732,711.47 compared to the same period last year[6] - Basic and diluted earnings per share fell by 33.33% to CNY 0.04[6] - Operating profit for Q1 2019 was ¥27,316,626.28, down 12.5% from ¥30,978,423.43 in Q1 2018[25] - Net profit for Q1 2019 was ¥21,158,809.18, a decrease of 17.5% compared to ¥25,707,907.52 in Q1 2018[27] - The total comprehensive income for Q1 2019 was ¥33,243,253.35, compared to ¥21,544,178.53 in Q1 2018, indicating a significant increase[27] - The total comprehensive income for Q1 2019 was CNY 10,706,512.58, compared to a loss of CNY 5,976,300.64 in Q1 2018, indicating a significant recovery[32] Assets and Liabilities - Total assets increased by 5.19% to CNY 3,288,857,308.54 compared to the end of the previous year[6] - The company's current assets totaled CNY 1,864,767,436.08, up from CNY 1,738,657,888.21, indicating an increase of about 7.2% year-over-year[16] - Total liabilities increased to CNY 667,232,279.95 from CNY 527,744,643.38, reflecting a rise of approximately 26.5%[18] - The total assets as of March 31, 2019, amounted to ¥2,037,177,086.62, up from ¥2,022,836,108.85 at the end of 2018[22] - Total liabilities increased to ¥50,328,786.60 in Q1 2019 from ¥46,394,321.41 in Q4 2018[22] - The total assets as of Q1 2019 were 3,126,491,309.12 RMB, unchanged from the previous year, indicating stability in asset management[40] - The total liabilities remained constant at 527,744,643.38 RMB, reflecting no significant changes in the company's debt structure[41] Cash Flow - Cash flow from operating activities surged by 202.16% to CNY 52,642,944.73 year-on-year[6] - Cash flow from operating activities generated a net inflow of CNY 52,642,944.73 in Q1 2019, a substantial increase from CNY 17,422,033.21 in Q1 2018[33] - The company reported cash inflow from financing activities of CNY 30,000,000.00 in Q1 2019, with a net cash flow from financing activities of CNY 21,193,456.33, compared to a net outflow of CNY 7,423,715.02 in Q1 2018[34] - The company incurred management expenses of CNY 1,704,893.10 in Q1 2019, down from CNY 1,842,185.56 in Q1 2018, reflecting a cost reduction of approximately 7.5%[29] - The total cash outflow from investing activities was CNY 5,932,435.30 in Q1 2019, a decrease from CNY 40,087,222.55 in Q1 2018, indicating reduced investment expenditures[34] Shareholder Information - The number of shareholders reached 51,199 at the end of the reporting period[10] - The company's equity attributable to shareholders rose to CNY 2,565,308,461.80, compared to CNY 2,539,856,196.66, showing a growth of about 1.0%[18] - Shareholders' equity totaled ¥1,986,848,300.02, an increase from ¥1,976,441,787.44 in the previous quarter[23] - The total equity attributable to shareholders was 2,539,856,196.66 RMB, remaining stable compared to the previous year, suggesting consistent shareholder value[41] Other Financial Metrics - The weighted average return on equity decreased by 0.29 percentage points to 0.93%[6] - Research and development expenses for Q1 2019 were ¥1,355,690.42, compared to ¥1,202,714.59 in Q1 2018, reflecting a growth of 12.7%[25] - The company reported other comprehensive income of CNY 12,084,444.17 in Q1 2019, a significant recovery from a loss of CNY 4,163,728.99 in Q1 2018[32] - The company experienced a foreign exchange loss of -54.16 RMB in Q1 2019, which is an improvement from -102.71 RMB in Q1 2018, reflecting better currency management[37]

Financial Performance - The company's operating revenue for 2018 was approximately ¥1.85 billion, representing a 6.75% increase compared to ¥1.74 billion in 2017[20]. - Net profit attributable to shareholders decreased by 18.14% to approximately ¥106 million from ¥130 million in the previous year[20]. - The net profit after deducting non-recurring gains and losses fell by 19.96% to approximately ¥96.66 million compared to ¥120.77 million in 2017[20]. - Basic earnings per share decreased by 16.67% to ¥0.20 from ¥0.24 in 2017[21]. - The weighted average return on equity decreased by 1.13 percentage points to 4.22% compared to 5.35% in the previous year[22]. - Total assets at the end of 2018 were approximately ¥3.13 billion, a slight increase of 0.99% from ¥3.10 billion in 2017[20]. - The company's net assets attributable to shareholders increased by 3.10% to approximately ¥2.54 billion compared to ¥2.46 billion at the end of 2017[20]. - The total profit for 2018 was 124.97 million yuan, a year-on-year decrease of 14.43%[61]. - The company achieved operating revenue of CNY 1,852,905,951.98, a year-on-year increase of 6.75%[80]. - Net profit attributable to shareholders was CNY 10,609.14 million, a decrease of 18.14% compared to the previous year[78]. - The company's total assets at the end of the year were CNY 312,649.13 million, with net assets attributable to shareholders increasing by 3.10% to CNY 253,985.59 million[78]. Risk Management - The company has detailed potential risks in the section discussing future development in the annual report[7]. - The company emphasizes the importance of investment risk awareness regarding forward-looking statements in the report[6]. - The company has a comprehensive risk analysis in the "Discussion and Analysis of Operating Conditions" section of the report[7]. - The company has established a strict quality control system to mitigate risks associated with product quality issues[157]. - The company acknowledges the risk of underperforming in drug development due to stringent regulatory requirements and the lengthy approval process[150]. - The company faces risks of its leading product being classified as an auxiliary drug, which could lead to a decline in sales of the sodium cantharidate series products[148]. - The company is committed to enhancing the evidence-based medical data for sodium cantharidate products to mitigate the risk of being classified as auxiliary drugs[149]. - The company is facing increased costs due to stricter environmental regulations, which could affect profitability[152]. Research and Development - The company focuses on eight major fields for drug research and development, including anti-tumor, cardiovascular, and pediatric medications[36]. - The company is conducting clinical research on its core anti-tumor product, with collaborations with 13 major cancer centers[63]. - The company invested CNY 100.58 million in the efficacy comparison study of the core product, sodium cantharidinate, which accounted for 0.05% of operating revenue, reflecting a decrease of 77.14% compared to the previous year[115]. - The company allocated CNY 68.51 million for the industrialization research of the compound amino acid (8) and vitamin (11) capsule, representing 0.04% of operating revenue, marking a 100% increase from the previous year[115]. - The company applied for 16 patents in 2018, including 7 invention patents and 9 design patents, and received 8 authorized patents[58]. - The company’s total R&D investment for the reporting period was CNY 22.85 million, which accounted for 1.24% of operating revenue and 0.88% of net assets[117]. - The company’s R&D investment is lower than the industry average of CNY 40.77 million, with competitors like Wuhua Pharmaceutical investing CNY 40.49 million, which is 5.23% of their operating revenue[117]. - The company is focusing on enhancing research and development for key potential products to improve efficacy and safety, while optimizing production processes[104]. Market and Sales Strategy - The company has built a specialized sales team and a nationwide sales network, covering both OTC and prescription drug markets[38]. - The company achieved operating revenue of 1,852.91 million yuan, a year-on-year increase of 6.75%[61]. - The company plans to expand its market presence and enhance product offerings in the coming year[84]. - The company will enhance R&D and innovation capabilities, focusing on core products in oncology and cardiovascular areas, with increased investment in R&D[137]. - The company aims to optimize its marketing layout to ensure the completion of all budget indicators for 2019, establishing a four-dimensional sales combination[143]. - The company will actively promote the construction of the Shawan project to optimize production capacity and create a sustainable development industrial park within three years[145]. - The company will continue to seek suitable targets for mergers and acquisitions to expand its scale and product line[137]. - The company is exploring new business models, including third-party logistics and partnerships, to expand its market presence[157]. Environmental and Social Responsibility - The company invested over 20 million RMB in environmental protection facilities and management at the Longli plant[186]. - The Longli plant achieved zero wastewater discharge through the implementation of a new wastewater treatment system[186]. - The company faced a fine of 200,000 RMB due to wastewater exceeding discharge standards, leading to a temporary production halt[189]. - After the environmental incident, the company established an emergency response team and upgraded the wastewater treatment system[190]. - The company provided professional training to nearly 1,000 grassroots doctors in various provinces as part of its social responsibility initiatives[183]. - The Longli plant has implemented a strict environmental protection management system, including a "one-vote veto" policy for environmental compliance[184]. - The company has been recognized as an advanced enterprise in poverty alleviation efforts by local authorities[184]. Corporate Governance - The company received a standard unqualified audit report from Lixin Accounting Firm[5]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for providing guarantees[7]. - The company has not made any changes to its stock structure during the reporting period[17]. - The company has not faced any administrative or criminal penalties related to the securities market during the reporting period[174]. - The company has not reported any major related party transactions that have not been disclosed in temporary announcements[177]. - The company has not faced any risks of suspension or termination of listing during the reporting period[173]. - The company has not engaged in any significant asset or equity acquisitions or disposals during the reporting period[179].

2019 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2019 年第一季度报告 2019 年 4 月 1 / 26 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2019 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 张芝庭 | 董事 | 公务 | 张涛涛 | | 段竞晖 | 独立董事 | 公务 | 王强 | 1.3 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 ...

Financial Performance - Net profit attributable to shareholders decreased by 19.67% to CNY 64,719,408.77 for the year-to-date period[6] - Operating revenue for the year-to-date period increased by 12.81% to CNY 1,294,026,311.76 compared to the same period last year[6] - Basic and diluted earnings per share decreased by 20.00% to CNY 0.12[7] - The weighted average return on equity decreased by 0.77 percentage points to 2.59%[7] - Total operating revenue for the third quarter was ¥437,003,796.03, a decrease of 2.9% compared to ¥448,629,318.37 in the same period last year[22] - Net profit for the first nine months reached ¥57,000,000, representing a significant increase from ¥40,000,000 in the same period last year[22] - The total profit for the first nine months of 2018 was 68,002,147.89 CNY, indicating a decrease from 77,421,426.58 CNY in the previous year[28] Assets and Liabilities - Total assets increased by 2.30% to CNY 3,167,050,298.34 compared to the end of the previous year[6] - Cash and cash equivalents decreased by 31.92% to ¥193,541,219.83 from ¥284,287,665.36 due to daily operating expenses[12] - Accounts receivable decreased by 43.88% to ¥86,045,215.68 from ¥153,323,781.32, attributed to daily operating expenses and bill discounts[12] - Total liabilities decreased to ¥46,998,196.54 from ¥88,968,506.84 at the beginning of the year, indicating improved financial stability[21] - The company's equity attributable to shareholders increased to ¥1,981,892,469.59 from ¥1,938,976,640.67 at the beginning of the year, reflecting a growth of 2.2%[21] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 117,351,551.10, a significant increase of 7,710.46% compared to the previous year[6] - Operating cash inflow for the first nine months of 2018 was CNY 1,453,110,229.70, an increase from CNY 1,352,554,917.35 in the same period last year, representing a growth of approximately 7.4%[32] - Cash inflow from financing activities totaled CNY 9,000,000.00, a decrease from CNY 168,200,000.00 in the previous year, showing reduced financing activities[33] - Net cash flow from financing activities was -CNY 140,501,613.50, a significant decline compared to CNY 86,697,356.73 in the same period last year, highlighting challenges in financing[33] Investments and Income - The company reported a total of CNY 12,134,623.81 in non-operating income for the year-to-date period[9] - Investment income rose by 161.63% to ¥693,822.60 from ¥265,191.51, indicating an increase in investment returns[13] - Other income increased by 123.13% to ¥14,512,100.00 from ¥6,503,777.00, primarily due to increased government subsidies[13] - The company reported investment income of 74,499,499.16 CNY for the first nine months of 2018, compared to 82,394,381.41 CNY in the previous year[28] Shareholder Information - The total number of shareholders at the end of the reporting period was 40,481[10] - The largest shareholder, Guizhou Magic Investment Co., Ltd., holds 24.59% of the shares, with 131,301,620 shares pledged[10] Operational Efficiency - The company has ongoing projects for production line upgrades and GMP certification, contributing to future growth[9] - Management expenses increased to 5,828,699.82 CNY for the first nine months of 2018, up from 4,158,645.34 CNY in the previous year[28] - The company's cash flow from operating activities was negatively impacted by a rise in cash payments to employees, which increased to CNY 110,146,612.77 from CNY 77,858,759.68, representing a growth of approximately 41.5%[32]

Financial Performance - The company's operating revenue for the first half of 2018 reached ¥857,022,515.73, representing a 22.71% increase compared to ¥698,405,154.78 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥58,570,939.08, up 14.42% from ¥51,190,591.28 in the previous year[21]. - The net cash flow from operating activities significantly improved to ¥97,621,314.18, a remarkable increase of 847.97% compared to a negative cash flow of ¥13,051,419.37 in the same period last year[21]. - The net profit after deducting non-recurring gains and losses was ¥48,485,691.08, showing a decrease of 7.08% compared to ¥52,182,784.27 in the same period last year[21]. - The company's basic and diluted earnings per share increased by 10% to CNY 0.11 compared to the same period last year[23]. - The total operating revenue for the current period reached ¥857,022,515.73, an increase of 22.7% compared to ¥698,405,154.78 in the previous period[104]. - Net profit for the current period was ¥52,011,052.91, representing a 12.0% increase from ¥46,264,332.35 in the previous period[104]. - The total profit for the current period was ¥66,376,462.46, an increase of 23.8% from ¥53,770,912.07 in the prior period[104]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,129,787,916.21, which is a 1.10% increase from ¥3,095,872,274.30 at the end of the previous year[21]. - The company's total liabilities decreased to ¥557,662,004.90 from ¥565,337,647.05, a reduction of about 1.2%[96]. - Owner's equity rose to ¥2,572,125,911.31, compared to ¥2,530,534,627.25, indicating an increase of approximately 1.6%[97]. - The company's cash and cash equivalents at the end of the reporting period were 228,031,202.20 RMB, down from 284,287,665.36 RMB at the beginning of the period[95]. - Accounts receivable decreased from 913,277,798.08 RMB to 875,480,075.49 RMB during the reporting period[95]. - Inventory decreased from 208,008,764.03 RMB to 196,460,038.00 RMB during the reporting period[95]. Operational Highlights - Operating revenue increased by CNY 158.62 million, a growth of 22.71%, driven by a 15.42% increase in pharmaceutical manufacturing sales and a 39.81% increase in pharmaceutical commerce[23]. - The proportion of revenue from pharmaceutical manufacturing was 65.93%, while pharmaceutical commerce accounted for 34.07% of total revenue[27]. - The company has established a comprehensive sales network with 24 self-built offices across the country, ensuring wide market coverage[28]. - The company’s main products include various medications for oncology, respiratory, cardiovascular, and gynecological treatments, showcasing a diverse product portfolio[27]. Research and Development - Research and development expenses increased by 63.16% to CNY 6.81 million, primarily due to increased payable settlements[42]. - The company aims to secure market access for its sodium cantharidate series products in various medical insurance directories to explore greater market potential and enhance profitability[51]. Risks and Challenges - The company faces risks from new medical reform policies and increased regulatory scrutiny, which may affect profitability due to price declines and changes in drug procurement policies[52]. - Rising raw material prices and supply constraints pose risks to profitability, as the company cannot pass these costs onto consumers due to price controls[54]. - The establishment of the National Healthcare Security Administration may lead to significant changes in drug procurement and pricing mechanisms, potentially reshaping the competitive landscape[53]. Shareholder Information - Shareholder Zhang Ya plans to reduce holdings by up to 26 million shares (4.87% of total shares), while Zhang Yan plans to reduce holdings by up to 1.28 million shares (0.24% of total shares)[81]. - The total number of ordinary shareholders at the end of the reporting period was 41,078[83]. - The largest shareholder, Guizhou Magic Investment Co., Ltd., held 131,301,620 shares, representing 27.39% of the total shares, with 43,600,000 shares pledged[85]. Compliance and Governance - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status[136]. - The company has maintained its ability to continue operations for at least 12 months following the reporting period, with no significant issues affecting its ongoing viability[135]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[141]. Environmental and Social Responsibility - The company invested over RMB 15 million in environmental protection facilities and management at the Longli branch as of June 2018[73]. - Longli branch was fined RMB 200,000 for exceeding wastewater discharge standards (COD exceeded by 1.2 times, BOD5 exceeded by 0.43 times) and was ordered to cease production for rectification[76].

Financial Performance - The company's operating revenue for 2017 was CNY 1,735,715,955.47, representing an increase of 8.63% compared to the previous year[21]. - The net profit attributable to shareholders decreased by 28.81% to CNY 129,601,273.60, primarily due to a decline in revenue from pharmaceutical production[21]. - Basic and diluted earnings per share fell by 29.41% to CNY 0.24, reflecting the decrease in net profit[22]. - The weighted average return on equity decreased by 2.49 percentage points to 5.35%, attributed to the decline in profits[23]. - The net profit after deducting non-recurring gains and losses was CNY 120,770,362.19, a decrease of 27.70% compared to the previous year[21]. - The company's total assets at the end of 2017 amounted to CNY 309,587.23 million, with net assets increasing by 4.43% to CNY 246,338.87 million[56]. - The total profit for the pharmaceutical manufacturing industry in 2017 was CNY 331.41 billion, with a year-on-year increase of 17.80%[42]. - The company reported a significant decline in cash flow from financing activities, down 75.86% to CNY 20,095,967.24[69]. Dividend Policy - The company plans to distribute a cash dividend of 0.3 RMB per 10 shares, totaling 16,022,148.84 RMB based on a total share capital of 534,071,628 shares as of December 31, 2017[4]. - The net profit attributable to ordinary shareholders for 2017 was 129,601,273.60 RMB, with a cash dividend payout ratio of 12.36%[152]. - The company has not made any adjustments to its cash dividend policy during the reporting period[151]. Research and Development - The company invested 2,387.32 million RMB in R&D during the reporting period, accounting for 1.38% of operating revenue and 0.94% of net assets[105]. - The R&D focus includes the development of the "Banmao Sodium" series products, with ongoing efficacy studies comparing them to mainstream anti-tumor drugs like Docetaxel[102]. - The company is conducting research on the processing and application of key medicinal materials, such as He Shou Wu, to improve product efficacy and reduce side effects[101]. - The company has ongoing R&D projects for various formulations, including the compound amino acid 8 vitamin 11 capsule, which is currently in the research phase[109]. Market and Industry Trends - The pharmaceutical manufacturing industry achieved a total revenue of CNY 2,818.55 billion, representing a year-on-year growth of 12.50%[42]. - The pharmaceutical industry is experiencing structural growth, with upstream sectors like chemical raw materials and traditional Chinese medicine leading in revenue and profit growth[42]. - The implementation of the two-invoice system starting in 2018 is expected to reduce the survival space for small and medium-sized pharmaceutical distribution companies[46]. - The competitive landscape in the chemical drug sector remains intense, with many domestic producers affected by the consistency evaluation policy[92]. Corporate Governance and Compliance - The company has provided a standard unqualified audit report from Lixin Accounting Firm[3]. - The company has a commitment to transparency in its financial reporting and governance practices[3]. - The company has maintained compliance with regulatory requirements and emphasized risk management in response to market changes[148]. - The actual controllers and major shareholders of the company have maintained a good integrity record without any administrative or criminal penalties during the reporting period[161]. Sales and Marketing Strategy - The company has established a comprehensive sales network covering most regions of the country, supported by a professional sales team[36]. - The company has implemented a four-dimensional sales strategy to enhance market penetration and achieve sales targets[36]. - The company is focusing on diversifying its development by exploring new investment management models and expanding into areas such as pharmaceutical retail and medical institution distribution[128]. Social Responsibility - The company is undertaking social responsibility initiatives, including the "Health China Action - Million Grassroots Doctors Continuing Education Project," to improve the skills of grassroots doctors[137]. - The company has invested over CNY 10 million in environmental protection facilities and management at its Longli branch[169]. - The Longli branch has implemented a natural gas boiler system to ensure compliant emissions, completing the upgrade in October 2017[169]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,752, down from 43,197 at the end of the previous month[175]. - The largest shareholder, Guizhou Magic Investment Co., Ltd., held 131,301,620 shares, representing 24.59% of the total shares[178]. - The company has no changes in the total number of ordinary shares and capital structure during the reporting period[174].

2018 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2018 年第一季度报告 2018 年 4 月 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2018 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 张芝庭 | 董事 | 公出 | 张涛涛 | | 段竞晖 | 独立董事 | 公出 | 王强 | 1.3 公司负责人张涛涛、主管会计工作负责人刚冲霞及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 ...